Bhinneka News Online: Reuters Health Report: April 24, 2017

Monday, 24 April 2017

Reuters Health Report: April 24, 2017

Click to View in Browser

Monday, April 24, 2017

Trump warns Democrats Obamacare will die without cash infusion

WASHINGTON (Reuters) - U.S. President Donald Trump warned Democrats on Sunday that Obamacare was in trouble and would die without government funding, apparently referring to the possibility of ending federal subsidies to help lower-income people buy health insurance.

Ghana, Kenya and Malawi to pilot GSK malaria vaccine from 2018

LONDON (Reuters) - Ghana, Kenya and Malawi will pilot the world's first malaria vaccine from 2018, offering it for babies and children in high-risk areas as part of real-life trials, the World Health Organization said on Monday.

Vaccination gaps lead to dangerous measles outbreaks in Europe: ECDC

LONDON (Reuters) - Gaps in vaccination coverage against measles have lead to several outbreaks of the highly-contagious disease in Europe in the past year, with both children and young adults affected, health officials said on Monday.

Becton Dickinson to acquire Bard for $24 billion

NEW YORK (Reuters) - U.S. medical equipment supplier Becton Dickinson and Co will acquire C R Bard Inc, in a $24 billion cash-and-stock deal, adding Bard's devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said on Sunday.

EU drugmakers urge June decision on new location for watchdog

FRANKFURT (Reuters) - Europe's drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc's medicines watchdog, which will relocate from London after Britain's decision to leave the EU.

Bristol-Myers NASH drug reduces liver fat in midstage study

(Reuters) - Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.

Uphill battle looms as Trump seeks revamped healthcare plan

WASHINGTON (Reuters) - President Donald Trump, striving to make good on a top campaign promise, is pushing his fellow Republicans who control Congress to pass revamped healthcare legislation but the same intraparty squabbling that torpedoed it last month could do it again.

FDA approves Samsung Bioepis' copy of J&J's Remicade: company

SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade, the first drug developed by the Samsung Group unit approved in the United States.

Valeant prices psoriasis treatment at $3,500 per month

(Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

(Reuters) - A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.